Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Barulli

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Clinical Chemistry|July 1, 1999
Prostate-specific antigen expression in normal human bone marrow cellsF Mannello, S Barulli, M Malatesta, et al.
Recenti Progressi in Medicina|July 1, 1995
[Idiopathic myelofibrosis. Main pathogenetic, prognostic and therapeutic aspects]S Barulli, S Rupoli, A Cinciripini, et al.
Recenti Progressi in Medicina|December 1, 1995
[Biologic aspects and clinical use of granulocyte growth factor]S Rupoli, N Battelli, S Del Prete, et al.
Leukemia & Lymphoma|December 29, 2004
Cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone (CDOP) plus rituximab is effective and well tolerated in poor performance status elderly patients with non-Hodgkin's lymphomaG Visani, B Guiducci, F D'Adamo, et al.
Haematologica|September 8, 1999
Low dose interferon-alpha2b combined with PUVA is an effective treatment of early stage mycosis fungoides: results of a multicenter study. Cutaneous-T Cell Lymphoma Multicenter Study GroupS Rupoli, S Barulli, B Guiducci, et al.
The Pharmacogenomics Journal|December 6, 2017
MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidineG Visani, F Loscocco, A Ruzzo, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Clinical Chemistry|July 1, 1999
Prostate-specific antigen expression in normal human bone marrow cellsF Mannello, S Barulli, M Malatesta, et al.
Recenti Progressi in Medicina|July 1, 1995
[Idiopathic myelofibrosis. Main pathogenetic, prognostic and therapeutic aspects]S Barulli, S Rupoli, A Cinciripini, et al.
Recenti Progressi in Medicina|December 1, 1995
[Biologic aspects and clinical use of granulocyte growth factor]S Rupoli, N Battelli, S Del Prete, et al.
Leukemia & Lymphoma|December 29, 2004
Cyclophosphamide, pegylated liposomal doxorubicin, vincristine and prednisone (CDOP) plus rituximab is effective and well tolerated in poor performance status elderly patients with non-Hodgkin's lymphomaG Visani, B Guiducci, F D'Adamo, et al.
Haematologica|September 8, 1999
Low dose interferon-alpha2b combined with PUVA is an effective treatment of early stage mycosis fungoides: results of a multicenter study. Cutaneous-T Cell Lymphoma Multicenter Study GroupS Rupoli, S Barulli, B Guiducci, et al.
The Pharmacogenomics Journal|December 6, 2017
MTHFR, TS and XRCC1 genetic variants may affect survival in patients with myelodysplastic syndromes treated with supportive care or azacitidineG Visani, F Loscocco, A Ruzzo, et al.
Pageof 1